I-SPY 2.2 Dato-DXd + Durva
I-SPY 2.2: Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in High-Risk Stage II-III HER2-Negative Breast Cancer

Released: June 07, 2024

Expiration: June 06, 2025

Activity

Progress
1
Course Completed